These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 25576919

  • 1. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D, Chen T, Li J, Fan J, Cong W, Gao Q, He X.
    Oncotarget; 2015 Feb 10; 6(4):2538-48. PubMed ID: 25576919
    [Abstract] [Full Text] [Related]

  • 2. miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.
    Song L, Zhang W, Chang Z, Pan Y, Zong H, Fan Q, Wang L.
    Med Sci Monit; 2017 Apr 10; 23():1741-1750. PubMed ID: 28394882
    [Abstract] [Full Text] [Related]

  • 3. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM, Xu Z, Shek FH, Wong KF, Lee NP, Poon RT, Chen J, Luk JM.
    PLoS One; 2014 Apr 10; 9(1):e86872. PubMed ID: 24466275
    [Abstract] [Full Text] [Related]

  • 4. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ, Yun JP.
    Oncotarget; 2015 Mar 30; 6(9):6570-83. PubMed ID: 25788265
    [Abstract] [Full Text] [Related]

  • 5. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q, Tu J, Dou C, Zhang J, Yang L, Liu X, Lei K, Liu Z, Wang Y, Li L, Bao H, Wang J, Tu K.
    Mol Cancer; 2017 Dec 20; 16(1):178. PubMed ID: 29262861
    [Abstract] [Full Text] [Related]

  • 6. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR, Tian MX, Yang LX, Lin YL, Jin L, Ding ZB, Shen YH, Peng YF, Gao DM, Zhou J, Qiu SJ, Dai Z, He R, Fan J, Shi YH.
    Oncotarget; 2015 Jan 20; 6(2):846-61. PubMed ID: 25514599
    [Abstract] [Full Text] [Related]

  • 7. TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma.
    Chen Z, Wang Z, Guo W, Zhang Z, Zhao F, Zhao Y, Jia D, Ding J, Wang H, Yao M, He X.
    Oncogene; 2015 Jul 23; 34(30):3946-56. PubMed ID: 25263439
    [Abstract] [Full Text] [Related]

  • 8. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
    Jia G, Wang Y, Lin C, Lai S, Dai H, Wang Z, Dai L, Su H, Song Y, Zhang N, Feng Y, Tang B.
    J Exp Clin Cancer Res; 2021 Sep 22; 40(1):299. PubMed ID: 34551796
    [Abstract] [Full Text] [Related]

  • 9. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP, Fako V, Dang H, Dominguez DA, Khatib S, Ma L, Wang H, Zheng W, Wang XW.
    J Exp Clin Cancer Res; 2020 Jun 03; 39(1):99. PubMed ID: 32487192
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma.
    Xu Q, Zhang M, Tu J, Pang L, Cai W, Liu X.
    Oncol Rep; 2015 Oct 03; 34(4):2054-64. PubMed ID: 26252254
    [Abstract] [Full Text] [Related]

  • 11. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO.
    PLoS One; 2014 Oct 03; 9(12):e115036. PubMed ID: 25541689
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Zhao R, Li L, Yang J, Niu Q, Wang H, Qin X, Zhu N, Shi A.
    Pathol Oncol Res; 2020 Apr 03; 26(2):853-860. PubMed ID: 30852741
    [Abstract] [Full Text] [Related]

  • 13. Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: from gene expression to drug discovery.
    Lv WW, Liu D, Liu XC, Feng TN, Li L, Qian BY, Li WX.
    BMC Cancer; 2018 Nov 21; 18(1):1150. PubMed ID: 30463528
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
    Chen YL, Song JJ, Chen XC, Xu W, Zhi Q, Liu YP, Xu HZ, Pan JS, Ren JL, Guleng B.
    World J Gastroenterol; 2015 Aug 14; 21(30):9093-102. PubMed ID: 26290635
    [Abstract] [Full Text] [Related]

  • 15. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
    Lin Y, Liu F, Fan Y, Qian X, Lang R, Gu F, Gu J, Fu L.
    Int J Clin Exp Pathol; 2015 Aug 14; 8(7):8028-37. PubMed ID: 26339369
    [Abstract] [Full Text] [Related]

  • 16. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
    Wang Q, Lu D, Fan L, Li Y, Liu Y, Yu H, Wang H, Liu J, Sun G.
    Int J Mol Med; 2019 Jan 14; 43(1):475-488. PubMed ID: 30365092
    [Abstract] [Full Text] [Related]

  • 17. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
    Fukuda S, Miyata H, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y.
    Ann Surg Oncol; 2015 Dec 14; 22 Suppl 3():S1461-8. PubMed ID: 25808097
    [Abstract] [Full Text] [Related]

  • 18. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
    Feng J, Wu L, Ji J, Chen K, Yu Q, Zhang J, Chen J, Mao Y, Wang F, Dai W, Xu L, Wu J, Guo C.
    J Exp Clin Cancer Res; 2019 May 17; 38(1):204. PubMed ID: 31101057
    [Abstract] [Full Text] [Related]

  • 19. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
    Jung Y, Jang YJ, Kang MH, Park YS, Oh SJ, Lee DC, Xie Z, Yoo HS, Park KC, Yeom YI.
    Mol Cells; 2013 Apr 17; 35(4):335-41. PubMed ID: 23515579
    [Abstract] [Full Text] [Related]

  • 20. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
    Chen D, Wang Y, Lu R, Jiang X, Chen X, Meng N, Chen M, Xie S, Yan GR.
    Theranostics; 2020 Apr 17; 10(19):8558-8572. PubMed ID: 32754263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.